Two large Xarelto™ studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease
Berlin, May 23, 2022 - Two studies with Bayer´s Factor Xa inhibitor rivaroxaban (Xarelto), the Long-Term Open Label Extension (LTOLE) ...
Read moreDetails

















